In agreement with our finding, Guerriero et al., demonstrated in an in vivo mouse cancer model that treatment with class IIa HDAC inhibitor TMP195 increased the anti-tumor potential of macrophages by pharmacologic modulation of the macrophage phenotype (26). Here, HDAC9 is linked to neoplasm.